Ferric carboxymaltose for sub-acute and chronic iron deficiency anemia in inherited platelet function defects.

Abstract

Inherited platelet function defects are characterized by sub-acute and chronic mucocutaneous bleedings leading to iron deficiency anemia (IDA). Oral supplementation is the mainstay of treatment of IDA; however, it can be insufficient to compensate the losses and is often associated with gastrointestinal (GI) side effects. Intravenous (IV) iron is indicated for severe anemia or to overcome GI intolerance. Previous IV iron formulations were limited by the risk of free iron toxicity and immunogenicity, while currently available compounds (ferumoxytol, iron isomaltoside and ferric carboxymaltose (FCM)) allow the administration of high doses with low immunogenicity. There are neither any randomized studies nor case reports evaluating the efficacy of FCM in patients with inherited platelet disorders. We herein present three cases of patients with IDA related to Glanzmann thrombasthenia and Bernard-Soulier syndrome, who have been successfully treated with FCM with increase in hemoglobin levels, reduced hospital visits and improvement in quality of life.

• Authors: Natalia Scaramellini, Marco Capecchi, Andrea Artoni, Silvia La Marca, Maria Domenica Cappellini, Irene Motta
• Journal: Internal and emergency medicine (Intern Emerg Med) Vol. 16 Issue 2 Pg. 505-507 (03 2021) ISSN: 1970-9366 [Electronic] Italy
• PMID: 32845453 (Publication Type: Case Reports, Letter)

Chemical References

• Ferric Compounds
• ferric carboxymaltose
• Maltose

Topics

• Administration, Intravenous
• Adult
• Aged
• Anemia, Iron-Deficiency (drug therapy)
• Female
• Ferric Compounds (administration & dosage, therapeutic use)
• Humans
• Maltose (administration & dosage, analogs & derivatives, therapeutic use)
• Thrombasthenia (genetics)